ARKK Holdings of CRISPR Therapeutics (CRSP) - Updated Daily
Join Premium Plan
Key Statistics
EarningsSee Full Calendar
| Date | May 09, 2022 | Revenue | Expected0 Actual$940.00k | EPS | Expected-$1.94 Actual-$2.32 |
|---|
Statistics
Clinical Trials (5)
Institutional Ownership Trends
News That Matters
| Description | |
|---|---|
| CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc.CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. | |
| Website | |
| crisprtx.com |
Research Notes and Commentary for CRSP
October 22, 2021
October 11-22: ARK Trades and Storylines
Trading Floor
October 8, 2021
October 7-8: ARK Trades and Storylines
Trading Floor
July 21, 2021
ARK Quarterly Webinar Summary and Notes
Trading Floor
December 18, 2020
For the first time in the history of the position Ark has stopped buying more CRSP...
Trading Floor
September 8, 2020
CRISPR Could Transform Body Fat into Energy and Weight Loss
See Section #1August 24, 2020
#236: Baidu’s Apollo Go Is A Smart Step Toward Launching Fully Autonomous Taxis, & More
See Section #3August 3, 2020
#233: Homeownership in the US is Skyrocketing, & More
See Section #3July 20, 2020